Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker

25 Aug 2021

Abstract excerpt

The evolution of coronaviruses, such as SARS-CoV-2, makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after. Here we report a human angiotensin-converting enzyme 2 (ACE2)-targeting monoclonal antibody, 3E8, blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2, SARS-CoV-2 mutant variants (SARS-CoV-2-D614G, B.1.1.7, B.1.351,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34433803
DOI: 10.1038/s41392-021-00740-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blockerPMID 34433803Read ↗

ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus BlockerSemantic proximity Read ↗

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsSemantic proximity Read ↗

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read ↗

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsSemantic proximity Read ↗

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read ↗

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodiesSemantic proximity Read ↗

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read ↗

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and aviditySemantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.